Refine by
Drug Discovery Program Articles & Analysis
3 articles found
Disease relevant mutations can be recapitulated or even correct by introducing a point mutation with a single base change, or by inserting/deleting large gene sequences. These endogenous knock-in cell lines enable a clear understanding of the contribution of the gene or mutation to a phenotype. There are unlimited uses for point mutation cell lines at pre-defined loci, including functional ...
By applying a proprietary operating system to drug discovery, the Utah clinical-stage biotechnology company expects to turn drug discovery from sequential testing into a search problem. Unmet clinical needs often serve as the fundamental driving force behind drug discovery programs. During lead discovery, an intensive search ensues to find a drug-like small molecule or biological therapeutic, ...
Insilico Medicine announced the nomination of a novel preclinical therapeutic candidate for treating COVID-19, designed using the generative chemistry AI platform Chemistry42. The new drug candidate is a 3CL protease inhibitor unique from existing drugs in its class because it can be rapidly produced. While this nomination is a potentially important development for the ongoing COVID-19 pandemic ...